



Dear Angelman Community,

Now, and always, the safety of families and individuals participating in our clinical trials is paramount. As we work to rapidly bring potential medicines to those affected by Angelman syndrome, our commitment to the community has never been stronger.

Ovid clinical trials are continuing. We are closely monitoring COVID-19 and the evolving impact on families in our clinical trials. Every location where our clinical trials are being conducted faces different challenges and disruptions, so it is crucial that families and site study teams remain in close contact. Ovid is in regular contact with each site to provide guidance. In the event you lose contact with your study team, please contact Ovid at clinicaltrials@ovidrx.com and we will provide immediate support.

Currently, Ovid has two ongoing clinical trials in Angelman syndrome: The Phase 3 NEPTUNE Study, and the Open-Label ELARA study. **Both of these clinical trials are proceeding.** The safety of every member of the Angelman community is the core focus for Ovid during this global crisis, and we plan to proceed with empathy, integrity and responsibility. Ovid is working around the clock with study teams at each site to address unforeseen challenges, and to remove obstacles for families participating in our trials.

For families currently enrolled in NEPTUNE and ELARA studies:

- Families should follow study protocols and contact their clinical trial site directly for guidance on upcoming visits, study procedures and any other concerns.
- If you are unable to contact your clinical trial site or are in need of additional information, please contact Ovid Therapeutics at: clinicaltrials@ovidrx.com and you will receive immediate response from a member of the Ovid team.

For families interested in participating in the NEPTUNE study:

- For those who are currently in screening, please contact your clinical trial site directly for guidance on next steps or with any other concerns.
- For those interested in participating, please visit www.angelmanstudy.com to learn more about the ongoing Phase 3 NEPTUNE study.

Our commitment to the Angelman community remains unwavering, and we will continue to provide updates on our clinical trials as the situation evolves. Know that we are with you in these challenging times, and we thank every member of this community for your support. Stay safe.

Best regards,

Jeremy M. Levin, D.Phil, MB BChir
Chairman and CEO

Tamara Agajanov, M.D.
VP, Global Clinical Operations